30 Results
December 2022
NIH Statement on World AIDS Day
December 1, 2022
In the 34 years since the first observance of World AIDS Day, transformational progress has been made in the global fight against HIV/AIDS, yet challenges remain. Today, we at the National Institutes of Health reflect on the 40 million lives lost to the disease and renew our commitment to the research necessary to end the global pandemic.
December 2021
NIH Statement on World AIDS Day
December 1, 2021
Since 1988, World AIDS Day has been an annual call to end the HIV/AIDS pandemic as we remember the many who lost their lives to the disease. Considerable progress has been made since the first World AIDS Day; however, far too many people continue to acquire HIV and die from its related illnesses. In 2020, an estimated 680,000 people globally died from HIV-related causes, and roughly 1.5 million people became newly infected with HIV, according to the World Health Organization (WHO).
November 2021
Too Many People with HIV Fail to Achieve Durable Viral Suppression
November 29, 2021
Among people with HIV worldwide who are receiving antiretroviral therapy (ART), adults are getting closer to the global target of 95% achieving viral suppression, but progress among children and adolescents is lagging and long-term viral suppression among all groups remains a challenge. These findings of a study funded by the National Institutes of Health suggest that substantial efforts are needed to help people with HIV durably suppress the virus. The findings were published today in the journal The Lancet HIV.
October 2021
NIH Researchers Identify How Two People Controlled HIV After Stopping Treatment
October 28, 2021
Research led by scientists at the National Institutes of Health has identified two distinct ways that people with HIV can control the virus for an extended period after stopping antiretroviral therapy (ART) under medical supervision. This information could inform efforts to develop new tools to help people with HIV put the virus into remission without taking lifelong medication, which can have long-term side-effects.
July 2021
NIH Awards More than $20 Million to International HIV Database Centers
July 22, 2021
The National Institutes of Health has renewed grants to seven regional centers that compose the International epidemiology Databases to Evaluate AIDS (IeDEA), awarding $20.8 million in first-year funding. The 15-year-old IeDEA program efficiently advances knowledge about HIV by pooling and analyzing de-identified health data from more than two million people with HIV on five continents to answer research questions that individual studies cannot address. The grants are expected to last five years and to total an estimated $100 million.
February 2021
To End HIV Epidemic, We Must Address Health Disparities
February 19, 2021
NIH reports that scientific strides in HIV treatment and prevention have reduced transmissions and HIV-related deaths significantly in the US.
January 2021
Antibody Infusions Prevent Acquisition of Some HIV Strains, NIH Studies Find
January 26, 2021
NIH finds that an investigational anti-HIV antibody prevented acquisition of some HIV strains, but did not significantly reduce overall acquisition.
November 2020
NIH Announces Restructured HIV Clinical Trials Networks
November 30, 2020
NIAID announced the clinical investigators and institutions that will lead four NIH HIV clinical trials networks over the next seven years.
Statement—NIH Study Finds Long-Acting Injectable Drug Prevents HIV Acquisition in Cisgender Women
November 9, 2020
A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every eight weeks was safe and more effective than a daily oral PrEP regimen at preventing HIV acquisition among a group of cisgender women. The women, from southern and east Africa, are enrolled in a clinical trial sponsored by the National Institutes of Health.
July 2020
Vaginal Ring for HIV Prevention Receives Positive Opinion from European Regulator
July 24, 2020
The European Medicines Agency (EMA) announces its adoption of a positive opinion on vaginal ring for HIV prevention.
Kidney Transplantation Between People with HIV is Safe, NIH Study Finds
July 23, 2020
NIH Study finds that kidney transplantation between people with HIV is safe, making more kidneys available for those awaiting a transplant.
Long-Acting Injectable Form of HIV Prevention Outperforms Daily Pill in NIH Study
July 7, 2020
In a recent NIH study, a long-acting injectable form of HIV prevention outperformed a daily pill.
May 2020
Long-Acting Injectable Drug Prevents HIV Among Men Who Have Sex with Men and Transgender Women
May 18, 2020
NIH study shows investigational long-acting form of the HIV drug cabotegravir prevents HIV acquisition in men and transgender women who have sex with men.
NIH Begins Clinical Trial of Hydroxychloroquine and Azithromycin to Treat COVID-19
May 14, 2020
A NIAID-sponsored clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine can prevent hospitalization and death from COVID-19.
February 2020
Recent Advances in Addressing Tuberculosis Give Hope for Future
February 11, 2020
NIAID Director Anthony S. Fauci, M.D., and other Institute officials summarize progress in improved TB diagnostics, therapeutics and prevention approaches.
NIH-Funded Clinical Trial to Test PrEP, Dapivirine Ring for Safety in Pregnant Women
February 10, 2020
The first clinical trial specifically designed to test the safety of the monthly dapivirine vaginal ring in pregnant women has begun in southern and eastern Africa. The National Institutes of Health-funded study also will test the safety of a daily oral antiviral tablet for HIV pre-exposure prophylaxis (PrEP) in pregnant women and will assess how much they accept and use these two HIV prevention tools. The study will complement an ongoing NIH-funded trial of PrEP in adolescents and young women during pregnancy and the first six months after birth.
January 2020
NIH-Supported Scientists Reverse HIV and SIV Latency in Two Animal Models
January 22, 2020
In a range of experiments, scientists have reactivated resting immune cells that were latently infected with HIV or its monkey relative, SIV, in cells in the bloodstream and a variety of tissues in animals. As a result, the cells started making copies of the viruses, which could potentially be neutralized by anti-HIV drugs and the immune system. This advance, published today in two papers in the journal Nature, marks progress toward a widely accessible cure for HIV.
October 2019
In Women with HIV, TB Preventive Therapy Poses Greater Risk in Pregnancy than Postpartum
October 2, 2019
Study results published today help clarify how to safely prevent tuberculosis (TB) in women living with HIV who are pregnant or have recently given birth, are taking antiretroviral therapy, and live where TB is highly prevalent.
September 2019
NIH Awards Contracts to Advance Tuberculosis Immunology Research
September 26, 2019
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded $30 million in first-year funding to establish new centers for immunology research to accelerate progress in tuberculosis (TB) vaccine development.
NIH Bolsters Funding for HIV Implementation Research in High-Burden U.S. Areas
September 5, 2019
The National Institutes of Health has awarded approximately $11.3 million to 23 institutions across the United States to collaborate with community partners to develop locally relevant plans for diagnosing, treating and preventing HIV in areas with high rates of new HIV cases.
July 2019
Most Women Use Vaginal Ring for HIV Prevention in Open-Label Study
July 23, 2019
In an open-label study of women in southern and eastern Africa, a vaginal ring that is inserted once a month and slowly releases an antiviral drug was estimated to reduce the risk of HIV by 39%, according to statistical modeling. In addition, the study found that participants appeared to use the ring more in the open-label study than in a previous clinical trial. These and other results of the HIV Open Label Extension (HOPE) study were presented today at the 10th IAS Conference on HIV Science (IAS 2019) in Mexico City.
Connection to HIV Care Helps Hardly Reached US Populations Suppress the Virus
July 22, 2019
Gay, bisexual and other men who have sex with men and transgender women with HIV, who are not in care, can be engaged in care when reached and connected with HIV treatment services, according to findings from a clinical trial supported by the National Institutes of Health. Nearly half of the study participants achieved and maintained viral suppression by one year, researchers reported today at the 10th IAS Conference on HIV Science (IAS 2019) in Mexico City.
NIH and Partners to Launch HIV Vaccine Efficacy Trial in the Americas and Europe
July 15, 2019
The National Institutes of Health and partners today announced plans to conduct a Phase 3 HIV vaccine efficacy trial at multiple clinical research sites in North America, South America and Europe. The trial, called HPX3002/HVTN 706 or Mosaico, will assess whether an investigational vaccine regimen designed to induce immune responses against a variety of global HIV strains can safely and effectively prevent HIV acquisition among men who have sex with men and transgender people.
June 2019
NIH Launches Large TB Prevention Trial for People Exposed to Multidrug-Resistant TB
June 25, 2019
A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB.
May 2019
HIV Vaccine Awareness Day 2019
May 18, 2019
Since initial reports in 1981, the effort to better understand, treat, and prevent HIV remains a critical focus for NIH, the US, and globally.
